Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.75 |
| ▸ | LPL | P06858 | 12/20 | 0.75 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24377142 | 1.00 | LIPG (0.75) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL24377089 | 1.00 | LIPG (0.75) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL24377081 | 1.00 | LIPG (0.75) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL24377088 | 0.97 | LIPG (0.79) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL29587465 | 0.97 | LIPG (0.79) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL10018882 | 0.97 | LIPG (0.79) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL24377031 | 0.97 | LIPG (0.79) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL24377051 | 0.97 | LIPG (0.79) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL24377082 | 0.94 | LIPG (0.68) | LIPGLPLDGAT1IRAK4ESR1 | |
| SCHEMBL24377079 | 0.94 | LIPG (0.80) | LIPGLPLDGAT1IRAK4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220131082-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220131082-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | NFE2L2, OR51E2, ETV6 | LIPG 1623/4885LPL 1617/4885DGAT1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.